Damora Therapeutics (DMRA) risk factors, FY2024 10-K

Risks Related to Our Financial Position and Need for Additional Capital

1. 01Following our strategic transaction with Bridge Medicines in October 2024, our focus is now on the development of GB3226 (previously referred to as BRM-1420) and GB1211. If we fail to execute successfully on this realigned strategic focus, our business and prospects will be adversely affected
2. 02We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs, future commercialization efforts or other operations
3. 03the costs of continuing to operate as a public company
4. 04Our independent registered public accounting firm has included an explanatory paragraph relating to our ability to continue as a going concern in its report on our audited financial statements included in this Annual Report on Form 10-K
5. 05We have incurred significant net losses since inception and we expect to continue to incur significant net losses for the foreseeable future
6. 06invest in or in-license other technologies or product candidates
7. 07SEC regulations limit the funds we can raise during 12 months under a shelf registration statement on Form S-3
8. 08The amount of our future losses is uncertain and our operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline
9. 09future accounting pronouncements or changes in our accounting policies

Risks Related to Research and Development and the Biotechnology and Biopharmaceutical Industry

1. 10We have a limited operating history, which may make it difficult to evaluate our prospects and likelihood of success
2. 11GB3226 is currently in preclinical development and we may fail to show that the drug is generally safe and well tolerated and that it may provide clinical benefit for patients
3. 12Clinical development involves a lengthy, complex and expensive process, with an uncertain outcome, and the results of preclinical studies and early-stage clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials
4. 13the proprietary rights of others and their competing products and technologies that may prevent one of our product candidates from being commercialized
5. 14We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our oncology or liver disease product candidates
6. 15the FDA or other comparable foreign regulatory authorities may require us to submit additional nonclinical data such as long-term toxicology studies or impose other requirements before permitting us to initiate a clinical trial
7. 16Our ongoing and future clinical trials may reveal significant adverse events or unexpected drug-drug interactions not seen in our preclinical studies and may result in a safety profile that could delay or prevent regulatory approval or market acceptance of any of our product candidates
8. 17If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected
9. 18the risk that patients enrolled in clinical trials will drop out of the trials before completion
10. 19The design or execution of our ongoing and future clinical trials may not support marketing approval or commercialization
11. 20We intend to develop certain of our product candidates and potentially other product candidates in combination with other therapies, which exposes us to additional risks
12. 21We may not be able to obtain orphan drug exclusivity for our product candidates, which could limit the potential profitability of such product candidates
13. 22Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay
14. 23We may not be successful in our efforts to identify or discover additional product candidates in the future
15. 24potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be medicines that will receive marketing approval and achieve market acceptance
16. 25Due to our limited resources and access to capital, we must make decisions on the allocation of resources to certain programs and product candidates; these decisions may prove to be wrong and may adversely affect our business
17. 26If product liability lawsuits are brought against us, we may incur substantial financial or other liabilities and may be required to limit commercialization of our product candidates
18. 27decline in our share price
19. 28We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do

Risks Related to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance

1. 29consent decrees or injunctions or the imposition of civil or criminal penalties
2. 30Even if a product candidate we develop receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success
3. 31the prevalence and severity of any side effects
4. 32Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, if approved, which could make it difficult for us to sell any product candidates profitably
5. 33neither experimental nor investigational
6. 34Even if we obtain FDA approval of any of our product candidates, we may never obtain approval or commercialize such products outside of the United States, which would limit our ability to realize their full market potential
7. 35The distribution of biotechnology and biopharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of biotechnology and biopharmaceutical products
8. 36Ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations
9. 37legislative changes enacted by Congress or programmatic changes implemented at CMS by the Trump Administration, may impact the IRA drug price negotiation program in the future
10. 38EU drug marketing and reimbursement regulations may materially affect our ability to market and receive coverage for our products in the European member states
11. 39We may incur substantial costs in our efforts to comply with evolving global data protection laws and regulations, and any failure or perceived failure by us to comply with such laws and regulations may harm our business and operations
12. 40Additional laws and regulations governing international operations, and the complexity associated with maintaining geographically diverse operations, could negatively impact or restrict our operations and ability to grow

Risks Related to Our Intellectual Property

1. 41Our success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection
2. 42We cannot be certain that we were the first to file any patent application related to our technology, including our product candidates, and, if we were not, we may be precluded from obtaining patent protection for our technology, including our product candidates
3. 43If we breach any of the agreements under which we license from third parties the commercialization rights to our product candidates, we could lose license rights that are important to our business and our operations could be materially harmed
4. 44We may enter into license or other collaboration agreements in the future that may impose certain obligations on us. If we fail to comply with our obligations under such future agreements with third parties, we could lose license rights that may be important to our future business
5. 45the priority of invention of patented technology
6. 46If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be negatively impacted, and our business and competitive position would be harmed
7. 47Third-party claims of intellectual property infringement may be costly and time consuming to defend, and could prevent or delay our product discovery, development and commercialization efforts
8. 48the need to redesign our product candidates or processes so they do not infringe, which may not be possible or may require substantial monetary expenditures and time
9. 49Third parties may assert that we are employing their proprietary technology without authorization
10. 50Third parties may assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets
11. 51Others may claim an ownership interest in our intellectual property, which could expose us to litigation and have a significant adverse effect on our prospects
12. 52Because our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license or use these proprietary rights
13. 53We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, or challenging the patent rights of others, which could be expensive, time-consuming and unsuccessful
14. 54Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
15. 55Any patents, if issued, covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO
16. 56Changes in patent law in the United States and in other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products
17. 57We have limited intellectual property rights outside of the United States and Europe and may not be able to protect and enforce our intellectual property rights throughout the world
18. 58Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time
19. 59If we do not obtain patent term extension and data exclusivity or similar non-U.S. legislation extending the term of protection covering any product candidates we may develop, our business may be materially harmed
20. 60If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected

Risks Related to Our Reliance on Third Parties

1. 61If any of our relationships with these third-party CROs or other third parties terminate, we may not be able to enter into arrangements with alternative CROs or other third parties or to do so on commercially reasonable terms
2. 62We depend on Rockefeller University to prosecute and maintain patents and patent applications that are material to our business. Any failure by a third party to effectively protect these intellectual property rights could adversely impact our business and operations
3. 63We rely on third parties for materials, including tissue samples, required for our research and development activities, and if we are unable to reach agreements with these third parties, our research and development activities would be delayed
4. 64in the event of approval to market and commercialize a product candidate, an inability to meet commercial demands for our products
5. 65collaborations may be terminated by the collaborator, and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates
6. 66Additionally, if one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our perception in the business and financial communities could be adversely affected

Risks Related to Managing Our Business and Operations

1. 67We may encounter difficulties in managing our organization, which could adversely affect our operations
2. 68improving our operational, financial and management controls, reporting systems and procedures
3. 69If we lose key management personnel, or if we fail to recruit additional highly skilled personnel, our ability to develop current product candidates or identify and develop new product candidates will be impaired, could result in loss of markets or market share and could make us less competitive
4. 70and business, the disclosure of confidential or proprietary information, including personal data, damage our reputation and subject us to significant financial and legal exposure
5. 71We or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters, and our business continuity and disaster recovery plans may not adequately protect us from any such serious disaster
6. 72Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations
7. 73The increasing use of social media platforms presents new risks and challenges
8. 74The estimates of market opportunity and forecasts of market growth included in this Annual Report on Form 10-K or that we may otherwise provide may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all
9. 75Our employees, independent contractors, consultants, commercial partners, collaborators and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
10. 76We use and generate materials that may expose us to material liability
11. 77If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
12. 78Compliance with governmental regulations regarding the treatment of animals used in research could increase our operating costs, which would adversely affect the commercialization of our products
13. 79Changes in U.S. tax law could adversely affect our financial condition and results of operations
14. 80Unanticipated changes in effective tax rates or adverse outcomes resulting from examination of our income or other tax returns could expose us to greater than anticipated tax liabilities
15. 81Our corporate structure and intercompany arrangements are subject to the tax laws of various jurisdictions, and we could be obligated to pay additional taxes, which would harm our results of operations
16. 82Our ability to use our net operating loss carryforwards and certain tax credit carryforwards may be subject to limitation
17. 83We may become involved in securities class action litigation that could divert management’s attention and harm the company’s business, and insurance coverage may not be sufficient to cover all costs and damages

Risks Related to Our Common Stock

1. 84The price of our stock may be volatile, which could result in substantial losses for our stockholders
2. 85other events or factors, many of which are beyond our control
3. 86Our failure to meet Nasdaq’s continued listing requirements could result in a delisting of our common stock
4. 87We do not intend to pay dividends on our common stock, so any returns will be limited to the value of our stock
5. 88We are an emerging growth company and a smaller reporting company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies will make our common stock less attractive to investors
6. 89Under the JOBS Act, EGCs can also delay adopting new or revised accounting standards until such time as those standards apply to private companies, which may make our financial statements less comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates
7. 90We will continue to incur significant costs as a result of operating as a public company, and our management may be required to devote substantial time to new compliance initiatives
8. 91Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
9. 92We have broad discretion in the use of our existing cash, cash equivalents and marketable securities and may not use them effectively
10. 93We can issue and have issued shares of preferred stock, which may adversely affect the rights of holders of our common stock
11. 94otherwise adversely affect the market price or our common stock
12. 95Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control, which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management
13. 96the authority of the board of directors to issue convertible preferred stock on terms determined by the board of directors without stockholder approval and which convertible preferred stock may include rights superior to the rights of the holders of common stock
14. 97If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline
15. 98Our amended and restated by-laws, as amended, will designate certain courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders’ ability to litigate disputes with us in a different judicial forum
16. 99Our issuance of additional capital stock in connection with financings, acquisitions, investments, our stock incentive plans or otherwise will dilute all other stockholders